U.S. Markets closed

Eli Lilly and Company (LLY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.74+0.08 (+0.09%)
At close: 4:03PM EDT

84.99 0.25 (0.30%)
After hours: 6:36PM EDT

People also watch
BMYMRKABTGSKJNJ
Full screen
Previous Close84.66
Open84.66
Bid84.45 x 400
Ask85.45 x 200
Day's Range84.51 - 85.53
52 Week Range64.18 - 86.72
Volume3,951,914
Avg. Volume3,559,839
Market Cap89.14B
Beta0.17
PE Ratio (TTM)40.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.46%)
Ex-Dividend Date2017-08-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Nasdaq Futures Fall On Google; 4 Stocks Near Buys With Earnings Due
    Investor's Business Daily13 minutes ago

    Nasdaq Futures Fall On Google; 4 Stocks Near Buys With Earnings Due

    Nasdaq futures fell Monday evening as Apple retreated following its Q2 earnings. Four stocks near buy points report earnings Tuesday morning, including GM and 3M.

  • Could This Small Biotech Break Out On A Tie-Up With Eli Lilly?
    Investor's Business Daily3 hours ago

    Could This Small Biotech Break Out On A Tie-Up With Eli Lilly?

    Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.

  • Reuters5 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.